JP2021532742A5 - - Google Patents
Info
- Publication number
- JP2021532742A5 JP2021532742A5 JP2021504286A JP2021504286A JP2021532742A5 JP 2021532742 A5 JP2021532742 A5 JP 2021532742A5 JP 2021504286 A JP2021504286 A JP 2021504286A JP 2021504286 A JP2021504286 A JP 2021504286A JP 2021532742 A5 JP2021532742 A5 JP 2021532742A5
- Authority
- JP
- Japan
- Prior art keywords
- nef
- domain
- tcr
- cells
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018097235 | 2018-07-26 | ||
| CNPCT/CN2018/097235 | 2018-07-26 | ||
| PCT/CN2019/097969 WO2020020359A1 (en) | 2018-07-26 | 2019-07-26 | Nef-containing t cells and methods of producing thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021532742A JP2021532742A (ja) | 2021-12-02 |
| JP2021532742A5 true JP2021532742A5 (enExample) | 2022-07-06 |
Family
ID=69181353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021504286A Pending JP2021532742A (ja) | 2018-07-26 | 2019-07-26 | Ｎｅｆを含むｔ細胞及びその生成方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220177524A1 (enExample) |
| EP (1) | EP3827075A4 (enExample) |
| JP (1) | JP2021532742A (enExample) |
| KR (1) | KR20210049806A (enExample) |
| CN (2) | CN112771154B (enExample) |
| AU (1) | AU2019312411A1 (enExample) |
| CA (1) | CA3103337A1 (enExample) |
| IL (1) | IL280240A (enExample) |
| MX (1) | MX2021000934A (enExample) |
| SG (1) | SG11202012253WA (enExample) |
| TW (1) | TW202020146A (enExample) |
| WO (1) | WO2020020359A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| CN115768899B (zh) * | 2020-03-09 | 2026-03-27 | 詹森生物科技公司 | 用于定量重组载体核酸整合的组合物和方法 |
| WO2022116086A1 (en) * | 2020-12-03 | 2022-06-09 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
| EP4259784A4 (en) * | 2020-12-14 | 2025-01-15 | Nanjing Legend Biotech Co., Ltd. | METHODS AND COMPOSITIONS FOR DEPOVERY OF NATURAL KILLER CELLS AND USES THEREOF IN CELLULAR THERAPIES |
| CA3207206A1 (en) * | 2021-02-01 | 2022-08-04 | Lingfeng LIU | Targeted protein degradation system and use thereof |
| CN117396498A (zh) * | 2021-03-18 | 2024-01-12 | 威斯塔解剖学和生物学研究所 | 靶向IL13Rα2的DNA编码的双特异性抗体以及在癌症治疗中的使用方法 |
| JP2024528077A (ja) * | 2021-07-30 | 2024-07-26 | ▲い▼尊生物医薬（浙江）有限公司 | 汎用型ｔ細胞およびその応用 |
| JP2024540275A (ja) * | 2021-11-04 | 2024-10-31 | ヤンセン バイオテック， インク． | Ｂｃｍａを標的とする、多発性骨髄腫のためのｃａｒ－ｔ細胞療法関連出願の相互参照 |
| WO2023077343A1 (en) * | 2021-11-04 | 2023-05-11 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
| JP2025524921A (ja) * | 2022-07-29 | 2025-08-01 | レジェンド バイオテック アイルランド リミテッド | 細胞療法の持続性を促進するための方法 |
| WO2024098037A1 (en) * | 2022-11-04 | 2024-05-10 | WUGEN, Inc. | Generation of cd3 expressing immune cells for use in conjunction with cd3 binding bispecific targeting agents |
| WO2024153211A1 (en) * | 2023-01-19 | 2024-07-25 | Nanjing Legend Biotech Co., Ltd. | Fusion polypeptides for targeted protein degradation and mehtods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1409694A4 (en) * | 2001-07-05 | 2006-02-08 | Chiron Corp | POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF |
| EP2420248A1 (en) * | 2004-08-17 | 2012-02-22 | Institut Gustave Roussy | Mutated HIV NEF for modulating immunity |
| US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| SG10201806573TA (en) * | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| ES2959480T3 (es) * | 2014-02-07 | 2024-02-26 | Univ Mcmaster | Acoplador de células T - antígeno trifuncional y métodos y usos del mismo |
| WO2015164759A2 (en) * | 2014-04-25 | 2015-10-29 | Bluebird Bio, Inc. | Mnd promoter chimeric antigen receptors |
| BR112018014585A2 (pt) * | 2016-01-21 | 2018-12-11 | Pfizer | receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii |
| AU2017248259A1 (en) * | 2016-04-07 | 2018-10-25 | Bluebird Bio, Inc. | Chimeric antigen receptor T cell compositions |
| AU2017326748A1 (en) * | 2016-09-14 | 2019-04-11 | Benitec Biopharma Limited | Reagents for producing T-cells with non-functional T-cell receptors (TCRs) compositions comprising same and use thereof |
| EP4759318A2 (en) * | 2017-04-14 | 2026-06-17 | The General Hospital Corporation | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| CN110520196A (zh) * | 2017-04-19 | 2019-11-29 | 艾洛基治疗公司 | 改进的t细胞组合物和方法 |
-
2019
- 2019-07-26 TW TW108126647A patent/TW202020146A/zh unknown
- 2019-07-26 KR KR1020217005328A patent/KR20210049806A/ko not_active Withdrawn
- 2019-07-26 AU AU2019312411A patent/AU2019312411A1/en not_active Abandoned
- 2019-07-26 CN CN201980062656.7A patent/CN112771154B/zh active Active
- 2019-07-26 SG SG11202012253WA patent/SG11202012253WA/en unknown
- 2019-07-26 JP JP2021504286A patent/JP2021532742A/ja active Pending
- 2019-07-26 CN CN202411827547.9A patent/CN119661659A/zh not_active Withdrawn
- 2019-07-26 WO PCT/CN2019/097969 patent/WO2020020359A1/en not_active Ceased
- 2019-07-26 CA CA3103337A patent/CA3103337A1/en active Pending
- 2019-07-26 MX MX2021000934A patent/MX2021000934A/es unknown
- 2019-07-26 US US17/262,787 patent/US20220177524A1/en not_active Abandoned
- 2019-07-26 EP EP19841972.3A patent/EP3827075A4/en not_active Withdrawn
-
2021
- 2021-01-18 IL IL280240A patent/IL280240A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024518011A5 (enExample) | ||
| JP2024507996A5 (enExample) | ||
| US12570743B2 (en) | BCMA-targeting engineered immune cell and use thereof | |
| AU2021307614B2 (en) | Engineered immune cell for allotransplantation | |
| US11180553B2 (en) | Chimeric antigen receptor | |
| US20190023764A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| AU2019288733A1 (en) | Chimeric transmembrane proteins and uses thereof | |
| US20250213708A1 (en) | Chimeric transmembrane proteins and uses thereof | |
| JP2024518011A (ja) | 多様な免疫細胞のための単鎖および多鎖合成抗原受容体 | |
| JP7699154B2 (ja) | 腫瘍微小環境を逆転させる融合タンパク質及びその使用 | |
| JP2019525956A5 (enExample) | ||
| JP2021514631A5 (enExample) | ||
| JP2020500530A5 (enExample) | ||
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| CN114015656A (zh) | 用于同种异体移植的工程化免疫细胞 | |
| CN111542545A (zh) | Cd38定向嵌合抗原受体构建体 | |
| JP2024510900A5 (enExample) | ||
| KR20230137923A (ko) | 신규한 키메라 항원 수용체 및 이의 용도 | |
| WO2018045034A1 (en) | Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain | |
| TW202432833A (zh) | 新穎ｃｄ１９結合體、包含彼之ｃａｒ—ｔ構築體及其使用方法 | |
| CN117683139A (zh) | 组成型嵌合细胞因子受体及表达其的免疫细胞及应用 | |
| JP2022521278A5 (enExample) | ||
| TW202430565A (zh) | 包含與il18組合之新穎cd19結合體之car-t構築體及其使用方法 | |
| WO2024179620A2 (zh) | 耐免疫排斥的工程化细胞 | |
| JP2025506515A5 (enExample) |